Clear Street initiated coverage of Zura Bio (ZURA) with a Buy rating and $18 price target The firm said he rating reflects “strong conviction” in tibulizumab’s ability to lead in hidradenitis suppurativa and systemic sclerosis. The firm also believes tibulizumab is well positioned to set a new standard.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZURA: